Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: ohnishi t. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.
Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer.
Yamamoto H, Tei M, Uemura M, Takemasa I, Uemura Y, Murata K, Fukunaga M, Ohue M, Ohnishi T, Ikeda K, Kato T, Okamura S, Ikenaga M, Haraguchi N, Nishimura J, Mizushima T, Mimori K, Doki Y, Mori M. Yamamoto H, et al. Among authors: ohnishi t. Int J Oncol. 2013 Feb;42(2):549-55. doi: 10.3892/ijo.2012.1750. Epub 2012 Dec 21. Int J Oncol. 2013. PMID: 23258614
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hata T, et al. Among authors: ohnishi t. Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31. Cancer Chemother Pharmacol. 2013. PMID: 23543294 Clinical Trial.
Survival benefit of oral tegafur/uracil and leucovorin as a first line therapy for elderly patients with advanced or metastatic colorectal cancer.
Murata K, Yamamoto H, Fukunaga M, Kato T, Ohnishi T, Uemura Y, Ohta H, Kimura F, Ohue M, Nezu R, Sekimoto M, Ikeda M, Mizushimaz T, Doki Y, Mori M; Clinical Study Group of Osaka University (CSGO) Colorectal Group. Murata K, et al. Among authors: ohnishi t. Hepatogastroenterology. 2014 Jan-Feb;61(129):94-8. Hepatogastroenterology. 2014. PMID: 24895801 Clinical Trial.
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Yamamoto H, Murata K, Fukunaga M, Ohnishi T, Noura S, Miyake Y, Kato T, Ohtsuka M, Nakamura Y, Takemasa I, Mizushima T, Ikeda M, Ohue M, Sekimoto M, Nezu R, Matsuura N, Monden M, Doki Y, Mori M. Yamamoto H, et al. Among authors: ohnishi t. Clin Cancer Res. 2016 Jul 1;22(13):3201-8. doi: 10.1158/1078-0432.CCR-15-2199. Epub 2016 Feb 1. Clin Cancer Res. 2016. PMID: 26831719
1,905 results